The supplied filings link Itamar Medical, Ltd. to a single 510(k) record: K260648 for PolySense, decided 30 October 2026 as substantially equivalent. FDA lists the applicant at 9 Halamish St., Caesarea, Israel, with product code GWL, regulation number 882.1835, device class 2 and the Neurology advisory committee. ZOLL Itamar describes itself as a division of ZOLL Medical, acquired in 2021, and markets WatchPAT home sleep apnea testing products. The record sample is one entry, so it describes a single clearance rather than the company's full portfolio. [1][2][6]
The PolySense clearance
K260648 was received by FDA on 27 February 2026 and decided on 30 October 2026 with decision code SESE, meaning substantially equivalent. The submission is a Traditional 510(k) with no third-party review, and FDA records a Summary as the statement or summary type. The device is listed as PolySense under product code GWL, device name Amplifier, Physiological Signal, class 2, regulation 882.1835, in the Neurology specialty. [1][2]
The applicant of record is Itamar Medical, Ltd., with the contact listed as Dafna Raiman and the address 9 Halamish St., Caesarea, postal code 3088900, country code IL. That address is the filing address in the FDA record and is not treated here as a corporate headquarters. The openFDA fields attached to the record also carry registration and FEI numbers, which identify facilities associated with the entry rather than products. [1][9]
PolySense accessories and the WatchPAT 400
ZOLL press releases state that PolySense accessories received FDA clearance and expand the ZOLL WatchPAT 400 from a home sleep apnea test to home polysomnography. The releases describe simple, self-applied head, cardiac and leg patches used with the WatchPAT 400, and characterize the combination as allowing a scalable range of routine to advanced sleep testing at home. These product descriptions come from ZOLL as publisher. [3][5]
The same releases note that product availability, approved indications for use and regulatory status may vary by jurisdiction, and that certain products may not be cleared or authorized for commercialization in a given region. The press releases do not state a clearance number for the accessories, so the link between the accessory announcement and K260648 is not established by the public documents. [3][5]
Documented product families
ZOLL Itamar's manuals page lists operating documentation for WatchPAT ONE, WatchPAT 300, WatchPAT 400, CloudPAT, zzzPAT, EndoPAT and EndoPATx devices, including a guide on viewing and editing WatchPAT signals. The company profile page describes ZOLL Itamar as a division of ZOLL Medical focused on sleep apnea diagnosis and management programs built around WatchPAT products and services, and states Itamar Medical was founded in 1997 and acquired by ZOLL in 2021. [4][6]
The company website describes WatchPAT as a home sleep apnea test that uses the peripheral arterial tonometry signal, and describes CloudPAT as a cloud-based platform for patient data transfer and sleep study interpretation. The site attributes SOC 2 Type II attestation and ISO/IEC 27001:2022 certification, certified by TÜV Rheinland, to CloudPAT. These are publisher statements about the platform, not findings of this profile. [7]
How to read the filing record
The supplied collection contains one linked 510(k) record, and its decision count shows one SESE decision; the record sample likewise contains that single entry, K260648. These figures describe the MedtechLedger snapshot of filings only and are not measures of total company sales, total portfolio or safety performance. No premarket approval, recall or other pathway record appears in the public information. [1][8]
FDA's own listing of 510(k) final decisions rendered since 1 October 2026 shows multiple applicants and devices decided on 30 October 2026, the same date as K260648. That listing is useful context for the decision date but does not add records for Itamar Medical, Ltd. Any product not named in the numbered sources remains unknown here. [8][9]


